Geode Capital Management LLC Sells 1,338 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Geode Capital Management LLC reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 2.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 56,448 shares of the biotechnology company’s stock after selling 1,338 shares during the quarter. Geode Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $8,428,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ASND. Signaturefd LLC increased its holdings in Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares during the last quarter. Pursue Wealth Partners LLC bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at approximately $217,000. Rhumbline Advisers increased its stake in shares of Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares during the last quarter. Algert Global LLC raised its holdings in shares of Ascendis Pharma A/S by 54.6% in the 2nd quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company’s stock worth $297,000 after purchasing an additional 770 shares during the period. Finally, Assetmark Inc. purchased a new position in Ascendis Pharma A/S in the third quarter valued at approximately $331,000.

Ascendis Pharma A/S Trading Up 0.2 %

NASDAQ:ASND opened at $138.00 on Friday. The company has a market capitalization of $8.37 billion, a P/E ratio of -17.08 and a beta of 0.67. The business’s 50-day moving average is $131.43 and its 200 day moving average is $133.13. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00.

Analysts Set New Price Targets

A number of brokerages have recently commented on ASND. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Citigroup upped their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Stifel Nicolaus boosted their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Bank of America upped their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $191.77.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.